David Kirk, Author at Labiotech.eu

About

David Kirk is a freelance writer and communications consultant with interests in synthetic biology, biotech, and sustainability. He has a PhD in molecular microbiology and has industrial experience developing living medicines.

Articles by David Kirk

In Depth 7 Dec 2020

Are We Still Friends? What Brexit Means for UK Synthetic Biology

Synthetic biology is one of the big strengths of UK science, but can the country uphold its vantage point after Brexit, without the support of the EU? (Disclaimer: At the…

December 7, 2020 - 8 minutesmins - By David Kirk

In Depth 22 Jul 2020

Artificial Intelligence: A Superpower in the Fight Against Covid-19

The rapid spread of Covid-19 around the world has left drug developers with limited time to identify drug candidates to fight the virus. Amid this crisis, artificial intelligence has proven…

July 22, 2020 - 8 minutesmins - By David Kirk

News and Trends 15 Jun 2020

Chilean Biotech Moves to France to Develop Anti-Mold Food Preservative

The startup Protera is moving from Santiago de Chile to Paris following a €5M Series A round that will let the company scale up the production of an antifungal protein…

June 15, 2020 - 4 minutesmins - By David Kirk

News and Trends 8 Jun 2020

UK Startup Launches with €10M to Detect Epigenetic Signs of Cancer in Blood

A seed round of €10.1M will fund the launch of the University of Oxford spinout Base Genomics, which aims to improve cancer detection by measuring epigenetic changes to tumor DNA…

June 8, 2020 - 3 minutesmins - By David Kirk

News and Trends 29 May 2020

AI Drug Discovery Firm Exscientia Closes €54M Series C

UK-based Exscientia has closed a Series C financing round of €54M ($60M) to develop its artificial intelligence (AI) technology to guide drug discovery. The Danish investor Novo Holdings led the…

May 29, 2020 - 3 minutesmins - By David Kirk

News and Trends 15 May 2020

Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide

Researchers in Germany and France have combined synthetic biology with microfluidics to create artificial photosynthetic droplets, which could lead to the production of organic chemicals and clean fuels that is…

May 15, 2020 - 3 minutesmins - By David Kirk

News and Trends 7 May 2020

EU Pitches Into €7.4B Fund Supporting Covid-19 Treatments & Vaccines

The European Commission and global donors have pledged €7.4 billion to a fund aimed at ensuring collaborative development and universal deployment of diagnostics, treatments, and vaccines for Covid-19. The Coronavirus…

May 7, 2020 - 4 minutesmins - By David Kirk

brainvectis askbio gene therapy neurology

News and Trends 28 Apr 2020

AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s

The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy company AskBio. AskBio’s gene therapy experience and…

April 28, 2020 - 3 minutesmins - By David Kirk

News and Trends 28 Apr 2020

Anti-Aging Treatments at Forefront of Astellas’ €80M UK Acquisition

Japanese pharma giant Astellas has acquired the UK biotech Nanna Therapeutics for up to €80M (£69.5M) in a deal to boost the development of drugs for unspecified age-related conditions and…

April 28, 2020 - 3 minutesmins - By David Kirk

microfluidics cell therapy gene therapy microfluidX

News and Trends 24 Apr 2020

UK Startup to Manufacture Cell and Gene Therapies with Microfluidics

The UK company MicrofluidX has closed a €1.6M (£1.4 M) seed funding round to develop a microfluidic platform that could produce cell and gene therapies more cheaply than conventional cell…

April 24, 2020 - 3 minutesmins - By David Kirk

epigenetics review cambridge epigenetix oryzon1

News and Trends 9 Apr 2020

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

An epigenetics drug developed by the Spanish biopharmaceutical company Oryzon has reduced aggressive behavior in patients with Alzheimer’s disease and improved the experience of their caregivers in a phase IIa…

April 9, 2020 - 4 minutesmins - By David Kirk

News and Trends 6 Apr 2020

UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients

The UK company Izana Bioscience is freely providing its phase III-ready anti-inflammatory antibody namilumab in a compassionate use program for the treatment of patients with coronavirus disease in Italy. In…

April 6, 2020 - 2 minutesmins - By David Kirk

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering